Open access · US-GOV via ClinicalTrials.gov Clinical trial

Sarcopenic Index and Related Factors in Patients With Type 2 Diabetes Applying to Tertiary Health Care Services

Authors not listed

Goztepe Prof Dr Suleyman Yalcın City Hospital · 2024

Chronic inflammation Telomerase activation Human Randomized controlled trial

Abstract

Sarcopenia, characterized by a progressive loss of skeletal muscle mass and function, is particularly common in individuals with T2DM and is often associated with insulin resistance, chronic inflammation and oxidative stress. The Sarcopenia Index (SI), calculated as serum creatinine divided by serum cystatin C, is a practical tool for assessing sarcopenia and is used in many clinical settings. In this study, we aimed to investigate the relationship between sarcopenic index and variables such as age, diabetes duration, diabetes control and complication-related parameters such as NT-proBNP and Fib4 score in patients with type 2 diabetes.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-07-02 MST

Cite this

APA

Anonymous. (2024). Sarcopenic Index and Related Factors in Patients With Type 2 Diabetes Applying to Tertiary Health Care Services. <em>Goztepe Prof Dr Suleyman Yalcın City Hospital</em>. https://clinicaltrials.gov/study/NCT06539923

Vancouver

Anonymous. Sarcopenic Index and Related Factors in Patients With Type 2 Diabetes Applying to Tertiary Health Care Services. Goztepe Prof Dr Suleyman Yalcın City Hospital. 2024.

BibTeX

@misc{anon2024Sarcop, title = {Sarcopenic Index and Related Factors in Patients With Type 2 Diabetes Applying to Tertiary Health Care Services}, author = {Anonymous}, journal = {Goztepe Prof Dr Suleyman Yalcın City Hospital}, year = {2024}, }